FDA Brief

Warning letters Food

FDA warning letter to

Blossom Nature, LLC

MediumIssued Feb 18, 2021Posted Feb 19, 2021Center for Food Safety and Applied Nutrition (CFSAN)

FDA told Blossom Nature its St. John's Wort supplement is an unapproved new drug because its website and Amazon page say it treats depression.

What happened

FDA reviewed the company's website, www.blossom-nature.com, in December 2020 and found it sent customers to the company's Amazon page to buy St. John's Wort. FDA then reviewed that Amazon listing, which carried claims such as "NATURAL ANTIDEPRESSANT," "treatment for depression, anxiety and stress," and "effective as prescribed antidepressants but with no side effects." There was no inspection; the findings come from a review of the websites only.

What FDA found

  1. The website and Amazon claims that the product treats depression, anxiety and seasonal affective disorder make it a drug, not just a supplement.

    Section 201(g)(1)(B) of the Act [21 U.S.C. § 321(g)(1)(B)]
  2. The product is not generally recognized as safe and effective for these uses, so it counts as a "new drug."

    Section 201(p) of the Act [21 U.S.C. § 321(p)]
  3. The company sells this new drug without the FDA approval that the law requires before marketing.

    Sections 301(d) and 505(a) of the Act [21 U.S.C. §§ 331(d), 355(a)]
  4. The product has no adequate directions for use, because treating depression safely needs a licensed practitioner, which makes it misbranded.

    Section 502(f)(1) of the Act [21 U.S.C. § 352(f)(1)]; 21 C.F.R. § 201.5
  5. Shipping this misbranded drug across state lines breaks the law.

    Section 301(a) of the Act [21 U.S.C. § 331(a)]

What FDA wants

FDA tells the company to correct the violations promptly and to write back within fifteen working days with the specific steps taken, plus documents showing how it will prevent repeat violations. If it believes there is no violation, it must send its reasoning and supporting information to FDAAdvisory@fda.hhs.gov.

Who should pay attention

  • supplement brands that make disease claims on their own websites
  • Amazon marketplace sellers of herbal supplements
  • marketers of St. John's Wort and mood-related products

This is a summary. Read the original letter on fda.gov.

Similar letters to other companies

  1. Natuzem

    FDA warned Mexico-based Natuzem for selling unapproved new drugs, including Reumofan Plus, to U.S. consumers online.

    High risk
  2. RonanRx, Inc. dba RonanRx

    FDA says RonanRx's website and X posts misbrand compounded semaglutide and tirzepatide with false or misleading claims.

    Low
  3. Calibrate IV Hydration

    FDA told Calibrate IV Hydration its umbilical cord and exosome IV products are unapproved drugs and unlicensed biologics.

    High risk
  4. Best Chinese Medicines LLC

    FDA warned Best Chinese Medicines LLC that five herbal products sold online are unapproved new drugs because their labeling claims to treat diseases.

    High risk